Cybin Physical
Date icon

Sep 20, 2022 | 09:00 BST

  • Doug Drysdale
    Doug Drysdale Cybin, CEO
Mushrooms for Breakfast?

We are delighted to host, alongside our friends at Ocean Wall, an intimate in-person breakfast presentation, discussion and Q&A with Doug Drysdale, CEO of Cybin Inc – the only NYSE listed psychedelic drug company.

With the market downturn and tricky times ahead, there is likely to be huge consolidation in this sector over the next 12 -18 months with only those with a strong balance sheet able to survive. Psychedelics aficionado, Christian Angermayer, predicted recently that only 5 or 6 companies will be around in 2 years’ time.  With a very healthy cash balance, Cybin will be able to continue with clinical trials and also take advantage of opportunities that arise during that time (they have already acquired a DMT clinical study from Entheon Biomedical).

With the sector at a more realistic valuation level and most of the meme stock retail owners having left the space – we believe that this is an interesting time to hear again about this fascinating sector.

Numbers are limited – so please register below to confirm your place.

Your questions, their answers, all under our roof. 

  • Health
  • Educational
  • Networking & Social
  • Micro cap
  • UK